GlassScriptPhysician profile
Donald M Elgin
NPI 1790892529
$1,756.34
in general payments reported to CMS, 2019-2025
28 companies · $168 in 2025
The $168 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $297 · 2021: $322 · 2022: $263 · 2023: $234 · 2024: $63.92 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $465.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $231.80 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $188.44 | 2019-2020 | |
| Novo Nordisk INC | $176.94 | 2019-2023 | Rybelsus, Ozempic, Tresiba |
| Lilly USA, LLC | $156.82 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $116.83 | 2020-2025 | |
| Astellas Pharma US INC | $111.88 | 2019-2021 | |
| Amgen INC. | $92.53 | 2019-2023 | Otezla, Repatha |
| Grifols USA, LLC | $89.09 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $69.43 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $59.60 | 2023-2025 | Rexulti |
| Amarin Pharma, INC. | $53.76 | 2020-2022 | |
| Glaxosmithkline, LLC. | $52.32 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $49.21 | 2019-2022 | |
| Alk-Abello, INC | $35.01 | 2023 | Grastek, Odactra, Ragwitek |
| Biohaven Pharmaceuticals, INC. | $28.15 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.41 | 2019-2025 | Jardiance |
| Eisai INC. | $26.69 | 2021 | |
| Abbott Laboratories | $24.61 | 2022 | |
| Electromed, INC. | $20.94 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.04 | 2022 | |
| Mannkind Corporation | $18.57 | 2022 | |
| Valinor Pharma, LLC | $17.40 | 2025 | Movantik |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.89 | 2019 | |
| Paratek Pharmaceuticals, INC. | $16.16 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $15.44 | 2025 | |
| Arbor Pharmaceuticals, INC. | $14.91 | 2021 | |
| Merck Sharp & Dohme LLC | $13.70 | 2019 | |
| Allergan, INC. | $11.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Elgin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.